Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
R3i editorial
22 August 2016

Prof. Jean Charles Fruchart, Prof. Michel Hermans, Prof. Pierre Amarenco
Atherogenic dyslipidaemia: a risk factor for silent coronary artery diseaseRead more...

Clinical trials aim to assess the impact of treatments on risk for cardiovascular events, hard clinical endpoints which can be readily and objectively evaluated.
 
However, this month’s Focus article raises the issue of asymptomatic coronary artery disease (CAD), especially in high risk patients such as those with type 2 diabetes, and how best to direct efforts to reduce the high residual risk of silent CAD.
Silent CAD is more common than previously thought. While estimates vary, depending on the population studied and assessment procedures, it is thought that 15-35% of high risk individuals may be affected...
PCSK9 and Atherosclerosis
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professors Jean Davignon (Vice-President of the R3i foundation), Jean-Charles Fruchart (President of R3i) and Michel Hermans (R3i General Secretary), the latest downloadable deck of 242 slides discusses the potential role for anti-PCSK9 mAbs in the future management of cardiovascular disease.
landmark study
22 August 2016

VADT: Reduced diabetic retinopathy progression on intensive glycaemic therapy with higher HDL cholesterol levelsRead more...

As shown previously and in this analysis, the Veterans Affairs Diabetes Trial showed no significant association between glycaemic treatment assignment or improved lipid management on the risk for DR onset and/or progression (1). However, this report highlights an interaction between glycaemic and lipid control, as...
focus on...
22 August 2016

Atherogenic dyslipidaemia and silent coronary artery disease in type 2 diabetesRead more...

Silent CAD in individuals with type 2 diabetes has long been a matter of clinical concern, with studies suggesting that about at least 20% of patients may be affected (1).  Even with multifactorial risk factor intervention, including management of LDL-C, the presence of silent CAD...
recent publication

Volanesorsen: favourable effects on atherogenic dyslipidaemia in type 2 diabetesRead more...

Volanesorsen, a second generation antisense inhibitor of apolipoprotein (apo) CIII,...
recent publication

Targeting atherogenic dyslipidaemia: the next lipid frontierRead more...

This timely perspective highlights the unmet clinical need due to...
recent publication

NIPPON DATA 90: Non-HDL cholesterol is a predictor of long-term coronary mortalityRead more...

Follow-up of the NIPPON DATA 90 prospective general population cohort...
recent publication

Anagliptin may mediate benefit via reduction in remnant cholesterolRead more...

The gliptins or dipeptidyl peptidase 4 (DPP4) inhibitors, are widely...
recent publication

Association of microvascular and macrovascular diabetic complicationsRead more...

The R3i has previously discussed the proposal that the presence...
recent publication

ACCORDION: Benefit of fenofibrate on diabetic retinopathy did not persist long-termRead more...

The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye...

What is residual risk ?

Residual risk of vascular events persisting in patients at treatment goals according to current standards of care or failing to meet goals, including risk related to dyslipidemia, high blood pressure, hyperglycemia, systemic inflammation and unhealthy lifestyles.

What is the Initiative ?

The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and micro-vascular complications in patients with atherogenic dyslipidemia, characterised by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care.